510(k) for UroMed:
This article was originally published in Clinica
Executive Summary
The FDA has cleared UroMed's brachytherapy seeds, used in the treatment of prostate cancer. The radioactive seeds are implanted close to the site of the tumour and destroy it by emitting radiation. Due to the closeness of the seeds to the cancer cells, surrounding tissue is barely affected.